Shengming Huang

US Patent:

20060003995, Jan 5, 2006

Filed:

Jun 30, 2005

Appl. No.:

11/173981

Inventors:

James Cook - Whitefish Bay WI, US
Hao Zhou - Milwaukee WI, US
Shengming Huang - Milwaukee WI, US
Chunchun Zhang - Nanuet NY, US

Assignee:

WISYS TECHNOLOGY FOUNDATION, INC. - Madison WI

International Classification:

A61K 31/5513
C07D 487/04

US Classification:

514221000, 540568000

Abstract:

The present invention provides compositions and methods of using stereospecific benzodiazepine derivatives, their salts and prodrugs for the treatment of anxiolytic or convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnotic, muscle relaxant and ataxic side-effects. The invention further provides pharmaceutical compositions for treatment of anxiolytic and convulsant disorders in subjects in need thereof, comprising a compound, prodrug or a salt having a chemical structure represented by any one of Formula I-XXI and a pharmaceutically-acceptable carrier.

US Patent:

20100004226, Jan 7, 2010

Filed:

Aug 7, 2009

Appl. No.:

12/537399

Inventors:

James M. Cook - Whitefish Bay WI, US
Hao Zhou - Milwaukee WI, US
Shengming Huang - Milwaukee WI, US
Chunchun Zhang - Nanuet NY, US

International Classification:

A61K 31/5513
C07D 243/14
C07D 487/04
C07D 487/16
A61P 25/22
A61K 31/5517
A61P 25/32
A61P 25/00

US Classification:

514220, 540504, 540506, 540571, 540568, 540556, 514221, 514219

Abstract:

The present invention provides compositions and methods of using stereospecific benzodiazepine derivatives, their salts and prodrugs for the treatment of anxiolytic or convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnotic, muscle relaxant and ataxic side-effects. The invention further provides pharmaceutical compositions for treatment of anxiolytic and convulsant disorders in subjects in need thereof, comprising a compound, prodrug or a salt having a chemical structure represented by any one of Formula I-IV, VI-XI, XV-XVIII and XX-XXI and a pharmaceutically-acceptable carrier.

US Patent:

20100261711, Oct 14, 2010

Filed:

Mar 17, 2010

Appl. No.:

12/725763

Inventors:

James M. Cook - Whitefish Bay WI, US
Rahul V. Edwankar - Milwaukee WI, US
Chitra R. Edwankar - Milwaukee WI, US
Shengming Huang - Milpitas CA, US
Hiteshkumar D. Jain - Mumbai, IN
Jie Yang - Rensselaer NY, US
Felix Rivas - Waukegan IL, US
Hao Zhou - Paramus NJ, US

Assignee:

WiSys Technology Foundation - Madison WI

International Classification:

A61K 31/5517
A61K 31/5513
A61P 25/00

US Classification:

514220, 514221

Abstract:

In preferred embodiments, the present invention provides methods of treatment and pharmaceutical compositions for the suppression, alleviation and prevention of seizures. The preferred embodiments of the present invention further relate to methods of treatment and pharmaceutical compositions using benzodiazepine derivatives that provide suppression, alleviation and prevention of seizures with reduced sedative and ataxic side effects.

US Patent:

20100317619, Dec 16, 2010

Filed:

May 13, 2010

Appl. No.:

12/779449

Inventors:

James Cook - Whitefish Bay WI, US
Shengming Huang - Milpitas CA, US
Rahul Edwankar - Milwaukee WI, US
Ojas A. Namjoshi - Milwaukee WI, US
Zhi-Jian Wang - Milwaukee WI, US

International Classification:

A61K 31/695
A61K 31/5517
A61K 31/551
A61K 31/5513
A61P 25/04
A61P 25/06

US Classification:

514 63, 514220, 514221, 514218

Abstract:

In preferred embodiments, the present invention provides methods of treatment and pharmaceutical compositions for the suppression, alleviation and prevention of the often chronic, severe and debilitating pain that can accompany inflammatory diseases and neuropathic insults, pain that is often unresponsive to conventional analgesic treatment. The preferred embodiments of the present invention further relate to methods of treatment and pharmaceutical compositions using benzodiazepine derivatives that provide suppression, alleviation and prevention of neuropathic pain, migraine-related pain and inflammatory pain with reduced sedative and ataxic side effects.